<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646397</url>
  </required_header>
  <id_info>
    <org_study_id>CZKI-CKD-001</org_study_id>
    <nct_id>NCT02646397</nct_id>
  </id_info>
  <brief_title>Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension</brief_title>
  <acronym>BEAHIT</acronym>
  <official_title>Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of fosinopril plus benidipine vs.
      fosinopril plus hydrochlorothiazide on the renal function during the 6-month treatment in CKD
      patients with HTN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic kidney dysfunction or injury which affected the health over three
      months were diagnosed with chronic kidney disease (CKD).China has a high prevalence of
      CKD.The prevalence, awareness, and treatment of hypertension (HTN) in non-dialysis CKD
      patients were 67.3%,85.8%, and 81.0%, respectively. The renin-angiotensin system inhibitors
      (RASI) including angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II type 1
      receptor blocker (ARB) have been deeply confirmed to have apparent reno-protective effect in
      patients with CKD.Co-administration of diuretics and calcium channel blockers (CCBs) with
      ACEIs or ARBs are the most common combinations. Hydrochlorothiazide plus RASIs are another
      widely used combination according to the synergetic function of antihypertensive action and
      offset mutual adverse effects. Until now, no large scale studies have compared the effect of
      initial treatment with two different combinations of antihypertensive drugs in CKD patients
      on the progression of kidney disease in China. Studies in the subsets of CKD (diabetes and
      non-diabetes, micro-albuminuria and macro-albuminuria) are urgently needed.We aimed to
      conduct a large scale study to compare L/T-type CCB and diuretic on the basis of ACEI in CKD
      with HTN on renal progression of CKD in China.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in estimated glomerular filtration rate</measure>
    <time_frame>Changes in eGFR at month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abnormal renal events</measure>
    <time_frame>From baseline to month 6</time_frame>
    <description>Number of participants with 30% reduction of eGFR, doubling of serum creatinine concentration,end-stage renal disease (eGFR&lt; 15 mL/min/1.73m²) or chronic dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 24 hour proteinuria</measure>
    <time_frame>From baseline to month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mean SBP</measure>
    <time_frame>From baseline to month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnornal cardiovascular events</measure>
    <time_frame>At month 6</time_frame>
    <description>Number of participants with cardiovascular morbidity (nonfatal stroke, non-fatal myocardial infarction, resuscitated sudden cardiac death, unstable angina; and coronary revascularization procedures) and cardiovascular mortality (death due to sudden cardiac death, fatal stroke, fatal myocardial infarction, congestive heart failure or other cardiovascular causes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From baseline to month 6</time_frame>
    <description>Number of participants with abnormal laboratory values and/or adverse events that are related to Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urinary albumin excretion</measure>
    <time_frame>From baseline to month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mean DBP</measure>
    <time_frame>From baseline to month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">508</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Fosinopril,benidipine combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus benidipine (4/8 mg）once daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosinopril,hydrochlorothiazide combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus hydrochlorothiazide (12.5/25 mg）once daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosinopril</intervention_name>
    <description>Fosinopril is an angiotensin-converting enzyme inhibitor.</description>
    <arm_group_label>Fosinopril,benidipine combination</arm_group_label>
    <arm_group_label>Fosinopril,hydrochlorothiazide combination</arm_group_label>
    <other_name>Fosinopril Sodium</other_name>
    <other_name>Squibb Brand of Fosinopril Sodium</other_name>
    <other_name>Fosinil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benidipine</intervention_name>
    <description>Benidipine is a dihydropyridine-derived calcium channel blocker.</description>
    <arm_group_label>Fosinopril,benidipine combination</arm_group_label>
    <other_name>benidipine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide is a diuretic medication.</description>
    <arm_group_label>Fosinopril,hydrochlorothiazide combination</arm_group_label>
    <other_name>HCTZ</other_name>
    <other_name>Dichlothiazide</other_name>
    <other_name>HydroDIURIL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with non-dialysis CKD at the enrollment and randomization eGFR≥ 30
             ml/min per 1.73 m2 at the enrollment and randomization SBP&gt; 130 mmHg and/or DBP &gt; 80
             mmHg at the enrollment and randomization. Patients could not receive more than two
             antihypertensive medications prior to our enrollment, and should discontinue the prior
             antihypertensive medications after the enrollment according to the investigators'
             advice.

          2. 24 h proteinuria &lt; 1.5g at the enrollment

          3. Patients who signed the informed consent form

          4. Baseline serum Cr &lt; 3 mg/dL at the enrollment and randomization

        Exclusion Criteria:

          1. Hypertensive crisis (SBP &gt; 180 mmHg and/or DBP&gt;110 mmHg)

          2. Refractory hypertension (taking &gt; 2 antihypertensive drugs more than a month, SBP
             still &gt; 160mm Hg or DBP &gt; 100mmHg)

          3. Baseline serum Cr &gt; 3 mg/dl, or kidney transplantation

          4. Patients diagnosed as severe cardiac arrhythmia (severe extra beats, supraventricular
             tachycardias, ventricular arrhythmias, or bradyarrhythmias), heart failure, NYHA &gt;Ⅲ,
             angina, stroke, left ventricular hypertrophy or myocardial infarction within 12 months
             prior to first visit.

          5. Patients diagnosed as cancer or severe sepsis

          6. Hematological system disorders: myelodysplastic syndrome, granulocytopenia,
             hypereosinophilic syndrome, polycythemia, thrombocytopenia, and et al.

          7. Restrictive pericarditis

          8. Systemic Lupus Erythematous

          9. Severe diabetes complications such as diabetic ketoacidosis, hyperosmolar coma,
             retinopathy, amputation, and et al.

         10. Patients diagnosed as hyperkalemia(&gt;5.5mmol/L) within 6 months or at the enrollment

         11. Renal artery stenosis or vascular embolism disease

         12. Patient is currently pregnant or lactational

         13. AST/ALT &gt; three times of the upper limit of standard value at the baseline

         14. Any severe allergy of CCB, diuretic or ACE inhibitor

         15. History of severe side effects of CCB, diuretic or ACE inhibitor; long-term use of
             non-steroidal anti-inflammatory drugs

         16. Use of other investigational drugs within 30 days or 5 half-lives of last visit,
             whichever is longer.

         17. Other unsuitable patients judged by the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changlin Mei</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Nephrology, Shanghai ChangZheng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changlin Mei, MD</last_name>
    <phone>0086 21 81885411</phone>
    <email>chlmei1954@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nephrology, Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>December 31, 2015</last_update_submitted>
  <last_update_submitted_qc>December 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Changlin Mei</investigator_full_name>
    <investigator_title>Professor, Director of Division of Nephrology</investigator_title>
  </responsible_party>
  <keyword>glomerular filtration rate</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Fosinopril</mesh_term>
    <mesh_term>Benidipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

